Ketamine, a racemic mixture consisting of (S)-and (R)-ketamine, has been in clinical use
since 1970. Although best characterized for its dissociative anesthetic properties, ketamine …

Clinical studies have demonstrated that a single sub-anesthetic dose of the dissociative
anesthetic ketamine induces rapid and sustained antidepressant actions. Although this …

A revamped interest in the study of hallucinogens has recently emerged, especially with
regard to their potential application in the treatment of psychiatric disorders. In the last …

Objective: Suicide is a public health crisis with limited treatment options. The authors
conducted a systematic review and individual participant data meta-analysis examining the …

Objective: The authors compared the efficacy of standard-of-care treatment plus intranasal
esketamine or placebo for rapid reduction of symptoms of major depression, including …

Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …

Mental disorders are rising while development of novel psychiatric medications is declining.
This stall in innovation has also been linked with intense debates on the current diagnostics …

Ketamine, a drug introduced in the 1960s as an anesthetic agent and still used for that
purpose, has garnered marked interest over the past two decades as an emerging treatment …

Suicide is the 15th most common cause of death worldwide. Although relatively uncommon
in the general population, suicide rates are much higher in people with mental health …

Background. Suicide is a devastating public health problem and very few biological
treatments have been found to be effective for quickly reducing the intensity of suicidal …